Interaction of autophagy and Toll-like receptors: A regulatory crosstalk - even in cancer cells?

G. Müzes, Miklós Constantinovits, István Furi, Z. Tulassay, F. Sípos

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Accumulating evidence indicates that the aberrantly altered process of autophagy is definitely involved in carcinogenesis. Nonetheless, Toll-like receptors (TLRs) sensing cell-derived pattern/danger-associated molecules also have the capacity to promote tumor development and immune escape. TLRs are usually expressed in immunocompetent cells, though several types of cancer cells have also been reported to display these innate immune receptors. On the other hand, however, both TLR- and autophagy-related signals may exert tumor suppressor mechanisms mainly in a cell-specific and context-dependent manner. The role of autophagy has been radically expanded, and now this machinery is considered as a fundamental eukaryotic cellular homeostatic process and integral component of the immune system influencing infection, inflammation and immunity. Recent studies have documented that TLRs and autophagy are interrelated in response to danger signals, furthermore there is a controling cross-talk among them to avoid deficient or excessive immunological effects. Although the potential interaction of autophagy and TLRs in cancer cells has not yet been clarified, it seems to be a critical aspect of cancer development and progression. Upon translation of basic knowledge into practice it is reasonable to speculate that modulation of the TLR-autophagy regulatory loop might be relevant for cancer treatment by providing further possible therapeutic targets.

Original languageEnglish
Pages (from-to)743-752
Number of pages10
JournalCurrent Drug Targets
Volume15
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Toll-Like Receptors
Autophagy
Crosstalk
Cells
Neoplasms
Tumors
Tumor Escape
Translational Medical Research
Oncology
Immune system
Machinery
Immune System
Immunity
Carcinogenesis
Modulation
Inflammation
Molecules
Infection

Keywords

  • Autophagy
  • Cancer
  • Inflammation
  • Innate immunity
  • Signaling pathways
  • TLRs

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine
  • Drug Discovery
  • Medicine(all)

Cite this

Interaction of autophagy and Toll-like receptors : A regulatory crosstalk - even in cancer cells? / Müzes, G.; Constantinovits, Miklós; Furi, István; Tulassay, Z.; Sípos, F.

In: Current Drug Targets, Vol. 15, No. 8, 2014, p. 743-752.

Research output: Contribution to journalArticle

@article{779cf11fbbfa40baaceca32b8a3d0358,
title = "Interaction of autophagy and Toll-like receptors: A regulatory crosstalk - even in cancer cells?",
abstract = "Accumulating evidence indicates that the aberrantly altered process of autophagy is definitely involved in carcinogenesis. Nonetheless, Toll-like receptors (TLRs) sensing cell-derived pattern/danger-associated molecules also have the capacity to promote tumor development and immune escape. TLRs are usually expressed in immunocompetent cells, though several types of cancer cells have also been reported to display these innate immune receptors. On the other hand, however, both TLR- and autophagy-related signals may exert tumor suppressor mechanisms mainly in a cell-specific and context-dependent manner. The role of autophagy has been radically expanded, and now this machinery is considered as a fundamental eukaryotic cellular homeostatic process and integral component of the immune system influencing infection, inflammation and immunity. Recent studies have documented that TLRs and autophagy are interrelated in response to danger signals, furthermore there is a controling cross-talk among them to avoid deficient or excessive immunological effects. Although the potential interaction of autophagy and TLRs in cancer cells has not yet been clarified, it seems to be a critical aspect of cancer development and progression. Upon translation of basic knowledge into practice it is reasonable to speculate that modulation of the TLR-autophagy regulatory loop might be relevant for cancer treatment by providing further possible therapeutic targets.",
keywords = "Autophagy, Cancer, Inflammation, Innate immunity, Signaling pathways, TLRs",
author = "G. M{\"u}zes and Mikl{\'o}s Constantinovits and Istv{\'a}n Furi and Z. Tulassay and F. S{\'i}pos",
year = "2014",
doi = "10.2174/1389450115666140522120427",
language = "English",
volume = "15",
pages = "743--752",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Interaction of autophagy and Toll-like receptors

T2 - A regulatory crosstalk - even in cancer cells?

AU - Müzes, G.

AU - Constantinovits, Miklós

AU - Furi, István

AU - Tulassay, Z.

AU - Sípos, F.

PY - 2014

Y1 - 2014

N2 - Accumulating evidence indicates that the aberrantly altered process of autophagy is definitely involved in carcinogenesis. Nonetheless, Toll-like receptors (TLRs) sensing cell-derived pattern/danger-associated molecules also have the capacity to promote tumor development and immune escape. TLRs are usually expressed in immunocompetent cells, though several types of cancer cells have also been reported to display these innate immune receptors. On the other hand, however, both TLR- and autophagy-related signals may exert tumor suppressor mechanisms mainly in a cell-specific and context-dependent manner. The role of autophagy has been radically expanded, and now this machinery is considered as a fundamental eukaryotic cellular homeostatic process and integral component of the immune system influencing infection, inflammation and immunity. Recent studies have documented that TLRs and autophagy are interrelated in response to danger signals, furthermore there is a controling cross-talk among them to avoid deficient or excessive immunological effects. Although the potential interaction of autophagy and TLRs in cancer cells has not yet been clarified, it seems to be a critical aspect of cancer development and progression. Upon translation of basic knowledge into practice it is reasonable to speculate that modulation of the TLR-autophagy regulatory loop might be relevant for cancer treatment by providing further possible therapeutic targets.

AB - Accumulating evidence indicates that the aberrantly altered process of autophagy is definitely involved in carcinogenesis. Nonetheless, Toll-like receptors (TLRs) sensing cell-derived pattern/danger-associated molecules also have the capacity to promote tumor development and immune escape. TLRs are usually expressed in immunocompetent cells, though several types of cancer cells have also been reported to display these innate immune receptors. On the other hand, however, both TLR- and autophagy-related signals may exert tumor suppressor mechanisms mainly in a cell-specific and context-dependent manner. The role of autophagy has been radically expanded, and now this machinery is considered as a fundamental eukaryotic cellular homeostatic process and integral component of the immune system influencing infection, inflammation and immunity. Recent studies have documented that TLRs and autophagy are interrelated in response to danger signals, furthermore there is a controling cross-talk among them to avoid deficient or excessive immunological effects. Although the potential interaction of autophagy and TLRs in cancer cells has not yet been clarified, it seems to be a critical aspect of cancer development and progression. Upon translation of basic knowledge into practice it is reasonable to speculate that modulation of the TLR-autophagy regulatory loop might be relevant for cancer treatment by providing further possible therapeutic targets.

KW - Autophagy

KW - Cancer

KW - Inflammation

KW - Innate immunity

KW - Signaling pathways

KW - TLRs

UR - http://www.scopus.com/inward/record.url?scp=84904728057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904728057&partnerID=8YFLogxK

U2 - 10.2174/1389450115666140522120427

DO - 10.2174/1389450115666140522120427

M3 - Article

C2 - 24852605

AN - SCOPUS:84904728057

VL - 15

SP - 743

EP - 752

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 8

ER -